4th Quarter - Report

ORGANOGENESIS INC. for ORGANOGENESIS INC.

Firm
Client
Income
—
Expenses
$100,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare reimbursement policy for chronic wound healing products Physician Fee Schedule regulations regarding reimbursement for chronic wound healing product

LobbyistCovered position, as disclosed
ARTHUR-PAUL PETROSINELLI —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Food and Drug Administration policy on chronic wound healing products S. 4348 (FDASLA Act of 2002), regarding Food and Drug Administration policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding Food and Drug Administration policy on chronic wound healing products H.R. 2617 (Consolidated Appropriations Act, 2023), Division FF, Title III, regarding Food and Drug Administration policy on chronic wound healing products

LobbyistCovered position, as disclosed
ARTHUR-PAUL PETROSINELLI —

Bills named: S. 4348 (117th), H.R. 2617 (117th), H.R. 7667 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.